HIV, HCV, and Viral Diseases

Over the years, our scientists have accumulated extensive experiences in the modeling of drugs for HIV, HCV, and other viral diseases, focusing on challenging issues in development such as compliance, viral dynamics, and drug resistance. Here is a link to a disguised case study on HIV drug disease modeling and on combining drug-disease and economic modeling to inform drug development decisions.

The market place for HIV and HCV drugs is highly competitive. In the area of HCV, many companies are currently developing small-molecule new therapies for this disease due to limitations of current standard-of-care. Our HCV Clinical Outcomes Database contains up-to-date trial outcome information on these new drugs in development and therefore provides our scientists a powerful tool in comparative analysis, trial design, as well as product positioning.